Piper Sandler Cuts Immunome (NASDAQ:IMNM) Price Target to $23.00

Immunome (NASDAQ:IMNM) had its price objective trimmed by Piper Sandler from $27.00 to $23.00 in a report released on Tuesday morning, Benzinga reports. The firm currently has an overweight rating on the stock.

A number of other analysts also recently issued reports on IMNM. Wedbush reaffirmed an outperform rating and issued a $33.00 target price on shares of Immunome in a research note on Thursday, July 25th. JPMorgan Chase & Co. began coverage on Immunome in a report on Tuesday, April 30th. They set an overweight rating and a $24.00 price target for the company. Finally, Guggenheim began coverage on Immunome in a report on Monday, April 15th. They set a buy rating and a $35.00 price target for the company. Six equities research analysts have rated the stock with a buy rating, Based on data from MarketBeat, the stock has a consensus rating of Buy and an average target price of $29.00.

Immunome Stock Down 1.9 %

Shares of IMNM stock traded down $0.27 during trading hours on Tuesday, hitting $13.68. 14,324 shares of the company’s stock were exchanged, compared to its average volume of 807,946. The firm has a 50 day moving average of $13.61 and a two-hundred day moving average of $17.52. Immunome has a fifty-two week low of $6.13 and a fifty-two week high of $30.96. The firm has a market cap of $820.38 million, a P/E ratio of -1.85 and a beta of 1.78.

Immunome (NASDAQ:IMNM) last posted its quarterly earnings data on Tuesday, May 14th. The company reported ($0.34) EPS for the quarter, beating the consensus estimate of ($0.80) by $0.46. Immunome had a negative return on equity of 37.33% and a negative net margin of 1,829.44%. The firm had revenue of $1.03 million during the quarter, compared to the consensus estimate of $4.00 million. On average, equities analysts forecast that Immunome will post -1.45 earnings per share for the current fiscal year.

Insider Transactions at Immunome

In other Immunome news, Director Jean Jacques Bienaime bought 2,000 shares of the business’s stock in a transaction dated Tuesday, May 21st. The shares were acquired at an average price of $13.57 per share, with a total value of $27,140.00. Following the transaction, the director now owns 9,615 shares of the company’s stock, valued at $130,475.55. The acquisition was disclosed in a filing with the SEC, which is accessible through this link. Corporate insiders own 8.60% of the company’s stock.

Institutional Inflows and Outflows

Several institutional investors have recently added to or reduced their stakes in IMNM. Cerity Partners LLC acquired a new position in Immunome during the fourth quarter worth approximately $656,000. Jump Financial LLC acquired a new position in Immunome during the fourth quarter worth approximately $172,000. Mayo Clinic acquired a new position in Immunome during the fourth quarter worth approximately $1,161,000. Avidity Partners Management LP purchased a new position in shares of Immunome in the 4th quarter valued at approximately $14,268,000. Finally, Clear Creek Financial Management LLC purchased a new position in shares of Immunome in the 1st quarter valued at approximately $547,000. Institutional investors and hedge funds own 44.58% of the company’s stock.

Immunome Company Profile

Immunome, Inc, a biotechnology company, develops targeted cancer therapies. The company's clinical asset comprises AL102, an investigational gamma secretase inhibitor currently in evaluation in a Phase 3 trial for the treatment of desmoid tumors; and preclinical assets consist of IM-1021, a receptor tyrosine kinase-like orphan receptor 1 and antibody-drug conjugates, as well as IM-3050, a fibroblast activation protein targeted radioligand therapy; and IM-4320, an anti-IL-38 immunotherapy candidate.